Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy

The use of levocarnitine for the treatment of valproic-acid-induced hyperammonemic encephalopathy (VHE) is reviewed. VHE is generally characterized by an acute onset of impaired consciousness, focal neurologic symptoms, and increased seizure frequency. The exact mechanism of VHE is unclear but relat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of health-system pharmacy 2012-01, Vol.69 (1), p.35-39
Hauptverfasser:	Mock, Christie M, Schwetschenau, Kristen H
Format:	Artikel
Sprache:	eng
Schlagworte:	Ammonia Carnitine Carnitine - deficiency Carnitine - therapeutic use Case reports Causes of Cofactors Complications and side effects Consciousness Diagnosis Divalproex Dosage and administration Drug therapy Encephalopathy Glutamic acid Humans hyperammonemia Hyperammonemia - chemically induced Hyperammonemia - drug therapy Isomers Kidney L-Carnitine Levocarnitine Metabolites Neurotoxicity Syndromes - drug therapy Overdose Physiological aspects Reviews Seizures Valproic acid Valproic Acid - adverse effects Valproic Acid - poisoning
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!